JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: The concentration- and time-dependent anti-proliferative effects of ZT55 were only observed in cells carrying activating JAK2 pathway mutations, not in ALL, AML, CML or wild type cell lines.